Patents by Inventor William F. Heath, Jr.

William F. Heath, Jr. has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-obesity proteins
    Patent number: 5569744
    Abstract: The present invention provides anti-obesity proteins, which when administered to a patient regulate fat tissue. Accordingly, such agents allow patients to overcome their obesity handicap and live normal lives with much reduced risk for type II diabetes, cardiovascular disease and cancer.
    Type: Grant
    Filed: February 6, 1995
    Date of Patent: October 29, 1996
    Assignee: Eli Lilly and Company
    Inventors: Margret B. Basinski, Richard D. DiMarchi, David B. Flora, William F. Heath, Jr., James A. Hoffmann, Brigitte E. Schoner, James E. Shields, David L. Smiley
  • Anti-obesity proteins
    Patent number: 5569743
    Abstract: The present invention provides anti-obesity proteins, which when administered to a patient regulate fat tissue. Accordingly, such agents allow patients to overcome their obesity handicap and live normal lives with much reduced risk for type II diabetes, cardiovascular disease and cancer.
    Type: Grant
    Filed: January 31, 1995
    Date of Patent: October 29, 1996
    Assignee: Eli Lilly and Company
    Inventors: Richard D. DiMarchi, David B. Flora, William F. Heath, Jr., James A. Hoffman, James E. Shields, David L. Smiley
  • Anti-obesity proteins
    Patent number: 5567803
    Abstract: The present invention provides anti-obesity proteins, which when administered to a patient regulate fat tissue. Accordingly, such agents allow patients to overcome their obesity handicap and live normal lives with much reduced risk for type II diabetes, cardiovascular disease and cancer.
    Type: Grant
    Filed: February 6, 1995
    Date of Patent: October 22, 1996
    Assignee: Eli Lilly and Company
    Inventors: Margret Basinski, Richard D. DiMarchi, David B. Flora, William F. Heath, Jr., James A. Hoffmann, Brigitte E. Schoner, James E. Shields, David L. Smiley
  • Anti-obesity proteins
    Patent number: 5567678
    Abstract: The present invention provides anti-obesity proteins, which when administered to a patient regulate fat tissue. Accordingly, such agents allow patients to overcome their obesity handicap and live normal lives with much reduced risk for type II diabetes, cardiovascular disease and cancer.
    Type: Grant
    Filed: January 31, 1995
    Date of Patent: October 22, 1996
    Assignee: Eli Lilly and Company
    Inventors: Richard D. DiMarchi, David B. Flora, William F. Heath, Jr., James A. Hoffmann, James E. Shields, David L. Smiley
  • Anti-obesity proteins
    Patent number: 5563244
    Abstract: The present invention provides anti-obesity proteins, which when administered to a patient regulate fat tissue. Accordingly, such agents allow patients to overcome their obesity handicap and live normal lives with much reduced risk for type II diabetes, cardiovascular disease and cancer.
    Type: Grant
    Filed: January 31, 1995
    Date of Patent: October 8, 1996
    Assignee: Eli Lilly and Company
    Inventors: Richard D. DiMarchi, David B. Flora, William F. Heath, Jr., James A. Hoffmann, James E. Shields, David L. Smiley
  • Anti-obesity proteins
    Patent number: 5563245
    Abstract: The present invention provides anti-obesity proteins, which when administered to a patient regulate fat tissue. Accordingly, such agents allow patients to overcome their obesity handicap and live normal lives with much reduced risk for type II diabetes, cardiovascular disease and cancer.
    Type: Grant
    Filed: January 31, 1995
    Date of Patent: October 8, 1996
    Assignee: Eli Lilly and Company
    Inventors: Richard D. DiMarchi, David B. Flora, William F. Heath, Jr., James A. Hoffmann, James E. Shields, David L. Smiley
  • Anti-obesity proteins
    Patent number: 5563243
    Abstract: The present invention provides anti-obesity proteins, which when administered to a patient regulate fat tissue. Accordingly, such agents allow patients to overcome their obesity handicap and live normal lives with much reduced risk for type II diabetes, cardiovascular disease and cancer.
    Type: Grant
    Filed: January 31, 1995
    Date of Patent: October 8, 1996
    Assignee: Eli Lilly and Company
    Inventors: Richard D. DiMarchi, David B. Flora, William F. Heath, Jr., James A. Hoffmann, James E. Shields, David L. Smiley
  • Anti-obesity proteins
    Patent number: 5559208
    Abstract: The present invention provides anti-obesity proteins, which when administered to a patient regulate fat tissue. Accordingly, such agents allow patients to overcome their obesity handicap and live normal lives with much reduced risk for type II diabetes, cardiovascular disease and cancer.
    Type: Grant
    Filed: February 6, 1995
    Date of Patent: September 24, 1996
    Assignee: Eli Lilly and Company
    Inventors: Margret B. Basinski, Richard D. DiMarchi, William F. Heath, Jr., Brigitte E. Schoner
  • Anti-obesity proteins
    Patent number: 5554727
    Abstract: The present invention provides anti-obesity proteins, which when administered to a patient regulate fat tissue. Accordingly, such agents allow patients to overcome their obesity handicap and live normal lives with much reduced risk for type II diabetes, cardiovascular disease and cancer.
    Type: Grant
    Filed: February 6, 1995
    Date of Patent: September 10, 1996
    Assignee: Eli Lilly and Company
    Inventors: Margret B. Basinski, Richard D. DiMarchi, William F. Heath, Jr., Brigitte E. Schoner
  • Protein kinase c inhibitors
    Patent number: 5552396
    Abstract: This invention provides novel bis-indolemaleimide macrocycle derivatives of the formula: ##STR1## The invention further provides the preparation, pharmaceutical formulations and the methods of use for inhibiting Protein Kinase C in mammals.
    Type: Grant
    Filed: June 1, 1995
    Date of Patent: September 3, 1996
    Assignee: Eli Lilly and Company
    Inventors: William F. Heath, Jr., Michael R. Jirousek, John H. McDonald, III, Christopher J. Rito
  • Anti-obesity proteins
    Patent number: 5552523
    Abstract: The present invention provides anti-obesity proteins, which when administered to a patient regulate fat tissue. Accordingly, such agents allow patients to overcome their obesity handicap and live normal lives with much reduced risk for type II diabetes, cardiovascular disease and cancer.
    Type: Grant
    Filed: February 6, 1995
    Date of Patent: September 3, 1996
    Assignee: Eli Lilly and Company
    Inventors: Margret B. Basinski, Richard D. DiMarchi, William F. Heath, Jr., Brigitte E. Schoner
  • Anti-obesity proteins
    Patent number: 5552522
    Abstract: The present invention provides anti-obesity proteins, which when administered to a patient regulate fat tissue. Accordingly, such agents allow patients to overcome their obesity handicap and live normal lives with much reduced risk for type II diabetes, cardiovascular disease and cancer.
    Type: Grant
    Filed: January 31, 1995
    Date of Patent: September 3, 1996
    Assignee: Eli Lilly and Company
    Inventors: Richard D. DiMarchi, David B. Flora, William F. Heath, Jr., James A. Hoffmann, James E. Shields, David L. Smiley
  • Anti-obesity proteins
    Patent number: 5552524
    Abstract: The present invention provides anti-obesity proteins, which when administered to a patient regulate fat tissue. Accordingly, such agents allow patients to overcome their obesity handicap and live normal lives with much reduced risk for type II diabetes, cardiovascular disease and cancer.
    Type: Grant
    Filed: February 6, 1995
    Date of Patent: September 3, 1996
    Assignee: Eli Lilly and Company
    Inventors: Margret B. Basinski, Richard D. DiMarchi, William F. Heath, Jr., Brigitte E. Schoner
  • Protein kinase C inhibitors
    Patent number: 5545636
    Abstract: The present invention discloses compounds of the general formula: ##STR1## The compounds are highly isozyme selective protein kinase C beta-1 and beta-2 isozyme inhibitors. Accordingly, the present invention provides a method of selectively inhibiting protein kinase C isozymes beta-1, and beta-2. As isozyme selective inhibitors of beta-1 and beta-2, the compounds are therapeutically useful in treating conditions associated with diabetes mellitus and its complications, as well as other disease states associated with an elevation of the beta-1 and beta-2 isozyme.
    Type: Grant
    Filed: October 18, 1994
    Date of Patent: August 13, 1996
    Assignee: Eli Lilly and Company
    Inventors: William F. Heath, Jr., John H. McDonald, III, Michael Paal, Gerd R uhter, Theo Schotten, Wolfgang Stenzel
  • Anti-obesity proteins
    Patent number: 5532336
    Abstract: The present invention provides anti-obesity proteins, which when administered to a patient regulate fat tissue. Accordingly, such agents allow patients to overcome their obesity handicap and live normal lives with much reduced risk for type II diabetes, cardiovascular disease and cancer.
    Type: Grant
    Filed: January 31, 1995
    Date of Patent: July 2, 1996
    Assignee: Eli Lilly and Company
    Inventors: Richard D. DiMarchi, David B. Flora, William F. Heath, Jr., James A. Hoffmann, James E. Shields, David L. Smiley
  • Anti-obesity proteins
    Patent number: 5525705
    Abstract: The present invention provides anti-obesity proteins, which when administered to a patient regulate fat tissue. Accordingly, such agents allow patients to overcome their obesity handicap and live normal lives with much reduced risk for type II diabetes, cardiovascular disease and cancer.
    Type: Grant
    Filed: January 31, 1995
    Date of Patent: June 11, 1996
    Assignee: Eli Lilly and Company
    Inventors: Richard D. DiMarchi, David B. Flora, William F. Heath, Jr., James A. Hoffmann, James E. Shields, David L. Smiley
  • Anti-obesity proteins
    Patent number: 5521283
    Abstract: The present invention provides anti-obesity proteins, which when administered to a patient regulate fat tissue. Accordingly, such agents allow patients to overcome their obesity handicap and live normal lives with much reduced risk for type II diabetes, cardiovascular disease and cancer.
    Type: Grant
    Filed: January 31, 1995
    Date of Patent: May 28, 1996
    Assignee: Eli Lilly and Company
    Inventors: Richard D. DiMarchi, David B. Flora, William F. Heath, Jr., James A. Hoffmann, James E. Shields, David L. Smiley
  • Pharmaceutical compounds
    Patent number: 5514706
    Abstract: This invention provides novel compounds and pharmaceutical methods comprising the administration of a compound of the Formula I: ##STR1## wherein n, m, R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are variables.
    Type: Grant
    Filed: November 21, 1994
    Date of Patent: May 7, 1996
    Assignee: Eli Lilly and Company
    Inventors: Samantha J. Ambler, William F. Heath, Jr., Jai P. Singh, Colin W. Smith, Lawrence E. Stramm
  • Urea, thiourea and guanidine derivatives
    Patent number: 5441984
    Abstract: The present invention provides novel urea, thiourea and guanidine derivatives, pharmaceutical formulations thereof and a method of using same to prevent diabetic complications.
    Type: Grant
    Filed: November 14, 1994
    Date of Patent: August 15, 1995
    Assignee: Eli Lilly and Company
    Inventors: William F. Heath, Jr., Jill A. Panetta, John K. Shadle
  • A-C-B proinsulin, method of manufacturing and using same, and intermediates in insulin production
    Patent number: 5304473
    Abstract: The instant invention provides novel molecules derived from the components of proinsulin using recombinant DNA technology. The invention provides molecules of the formula A--C--B wherein A is the A-chain of an insulin species, B is the B-chain of an insulin species and C is a connecting peptide. These molecules possess insulin-like activity and are useful for the treatment of diabetes mellitus, particularly non-insulin dependent diabetes mellitus. These molecules are also useful for the production of insulin and constitute a novel pathway for the recombinant production of insulin species. The invention provides a method of making insulin proceeding through the compounds of the invention as intermediates. The instant invention further provides recombinant DNA compounds which encode the compounds of the invention.
    Type: Grant
    Filed: June 11, 1991
    Date of Patent: April 19, 1994
    Assignee: Eli Lilly and Company
    Inventors: Rama M. Belagaje, Richard D. DiMarchi, William F. Heath, Jr., Harlan B. Long